Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.46 |
| ▸ | CA2 | P00918 | 14/20 | 0.46 |
| ▸ | CA12 | O43570 | 11/20 | 0.46 |
| ▸ | CA9 | Q16790 | 11/20 | 0.46 |
| ▸ | CA4 | P22748 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404710 | 0.89 | ALDH1A1 (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL3474675 | 0.85 | CA1 (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1825183 | 0.84 | CA1 (0.48) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2404524 | 0.82 | CA1 (0.50) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1135639 | 0.81 | MAPT (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2409586 | 0.81 | LMNA (0.61) | CA1CA2CA12CA9MEN1 | |
| SCHEMBL2404339 | 0.81 | CA1 (0.63) | CA1CA2CA12CA9CA4 | |
| SCHEMBL13111190 | 0.80 | CA1 (0.53) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1824190 | 0.80 | CA1 (0.49) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1827138 | 0.80 | CA1 (0.50) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | CA1 4452/4885CA2 1155/4885CA12 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.